CATALYST PHARMACEUTICALS, INC. (CPRX) — SEC Filings

Latest SEC filings for CATALYST PHARMACEUTICALS, INC. (CPRX), explained in plain English.

Sentiment Overview: 1 bullish, 1 bearish, 42 neutral, 1 mixed

Recent Filings (45)

• 10-Q Filing — 10-Q · 2025-11-05T00:00:00.000Z [neutral]
• Catalyst Pharmaceuticals Files 8-K — 8-K · 2025-10-01T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed an 8-K on October 1, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is based
• Catalyst Pharmaceuticals Files 8-K/A Amendment — 8-K/A · 2025-08-28T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed an amendment (8-K/A) on August 28, 2025, to its current report originally filed on August 25, 2025. This amendment pertains
• Catalyst Pharmaceuticals Files 8-K — 8-K · 2025-08-25T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed an 8-K on August 25, 2025, reporting on other events and financial statements. The filing details the company's corporate s
• Catalyst Pharmaceuticals Files 8-K — 8-K · 2025-08-07T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed an 8-K on August 7, 2025, reporting an event that occurred on August 6, 2025. The filing is categorized under 'Other Events
• Catalyst Pharmaceuticals Files 8-K — 8-K · 2025-08-06T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed an 8-K on August 6, 2025, reporting other events and financial statements. The filing details the company's corporate infor
• Catalyst Pharma Files Q2 2025 10-Q — 10-Q · 2025-08-06T00:00:00.000Z [neutral] Risk: medium
  Catalyst Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2025. The company reported sales revenue net for Customer A and provided details on
• Catalyst Pharmaceuticals Files 8-K: Director Changes & Officer Compensation — 8-K · 2025-08-04T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed an 8-K on August 4, 2025, reporting on the departure of a director, election of a new director, and changes in compensatory
• Catalyst Pharmaceuticals Files 8-K — 8-K · 2025-06-02T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed an 8-K on June 2, 2025, reporting an event that occurred on June 1, 2025. The filing indicates 'Other Events' and 'Financia
• Catalyst Pharmaceuticals Files 8-K on Director, Officer, and Compensation Changes — 8-K · 2025-05-23T00:00:00.000Z [neutral] Risk: medium
  Catalyst Pharmaceuticals, Inc. announced on May 20, 2025, changes in its board of directors and executive compensation arrangements. The company also reported o
• Catalyst Pharmaceuticals Files 8-K — 8-K · 2025-05-07T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed an 8-K on May 7, 2025, reporting other events and financial statements/exhibits. The filing does not contain specific detai
• Catalyst Pharmaceuticals Files Q1 2025 10-Q — 10-Q · 2025-05-07T00:00:00.000Z [neutral] Risk: medium
  Catalyst Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business operations. K
• Catalyst Pharmaceuticals Files 2025 DEF 14A — DEF 14A · 2025-04-11T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed a DEF 14A on April 11, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and ot
• Catalyst Pharmaceuticals Files 8-K — 8-K · 2025-04-09T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed an 8-K on April 9, 2025, reporting an event that occurred on April 8, 2025. The filing is categorized under 'Other Events'
• Catalyst Pharmaceuticals Files 8-K — 8-K · 2025-02-26T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed an 8-K on February 26, 2025, reporting other events and financial statements. The filing details the company's corporate in
• Catalyst Pharmaceuticals Files 2024 10-K — 10-K · 2025-02-26T00:00:00.000Z [neutral] Risk: medium
  Catalyst Pharmaceuticals, Inc. filed its 2024 10-K on February 26, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on pharmace
• Catalyst Pharmaceuticals Appoints New Director — 8-K · 2025-01-24T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. announced on January 17, 2025, a change in its board of directors. Specifically, Dr. Richard J. Peterson has been appointed as a
• Catalyst Pharmaceuticals Files 8-K — 8-K · 2025-01-21T00:00:00.000Z [neutral] Risk: low
  On January 21, 2025, Catalyst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine cor
• Catalyst Pharmaceuticals Files 8-K — 8-K · 2025-01-13T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not
• Catalyst Pharmaceuticals Files 8-K — 8-K · 2025-01-08T00:00:00.000Z [neutral] Risk: low
  On January 8, 2025, Catalyst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific materi
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-08T00:00:00.000Z [neutral]
• Catalyst Pharmaceuticals Files 8-K — 8-K · 2024-11-06T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed an 8-K on November 6, 2024, reporting other events and financial statements. The filing details the company's incorporation
• Catalyst Pharma Q3: Strong Royalties, Capital Gains — 10-Q · 2024-11-06T00:00:00.000Z [mixed] Risk: medium
  Catalyst Pharmaceuticals, Inc. reported its third quarter 2024 results for the period ending September 30, 2024. The company's revenue from sales of Firdapse an
• SC 13G/A Filing — SC 13G/A · 2024-10-18T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-10-17T00:00:00.000Z [neutral]
• Catalyst Pharma to Acquire New Product — 8-K · 2024-09-26T00:00:00.000Z [neutral] Risk: medium
  Catalyst Pharmaceuticals, Inc. announced on September 24, 2024, that it has entered into a definitive agreement to acquire a pharmaceutical product from a third
• Catalyst Pharmaceuticals Files 8-K — 8-K · 2024-08-07T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed an 8-K on August 7, 2024, reporting other events and financial statements/exhibits. The company, incorporated in Delaware,
• Catalyst Pharma Q2 Revenue Up, Acquires FYCOMPA Rights — 10-Q · 2024-08-07T00:00:00.000Z [bullish] Risk: medium
  Catalyst Pharmaceuticals, Inc. reported its Q2 2024 results, ending June 30, 2024. The company generated $196.6 million in net product revenue for the six month
• Catalyst Pharma Acquires Firdapse Rights — 8-K · 2024-07-26T00:00:00.000Z [neutral] Risk: medium
  Catalyst Pharmaceuticals, Inc. announced on July 24, 2024, that it has entered into a definitive agreement to acquire the U.S. rights to Firdapse from Adare Pha
• Catalyst Pharmaceuticals Files 8-K — 8-K · 2024-05-30T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed an 8-K on May 30, 2024, to report other events and financial statements. The filing does not contain specific details on ne
• Catalyst Pharma Unveils New Equity Incentive Plan — 8-K · 2024-05-21T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. announced on May 21, 2024, that its Board of Directors has approved a new equity incentive plan, the 2024 Equity Incentive Plan.
• Catalyst Pharma Q1: FYCOMPA® Distribution Shift, Santhera Payment Complete — 10-Q · 2024-05-08T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. reported its first quarter 2024 results, ending March 31, 2024. The company fully paid the $5.9 million related to an investment
• Catalyst Pharma Proxy: Executive Pay Details Revealed — DEF 14A · 2024-04-10T00:00:00.000Z [neutral] Risk: medium
  Catalyst Pharmaceuticals, Inc. filed its DEF 14A on April 10, 2024, detailing executive compensation for the fiscal year ending December 31, 2023. The filing in
• Catalyst Pharmaceuticals Files 8-K — 8-K · 2024-03-13T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed an 8-K on March 13, 2024, to report other events and financial statements. The filing does not contain specific details on
• Catalyst Pharma Files Routine 8-K, No New Material Events — 8-K · 2024-02-29T00:00:00.000Z [neutral] Risk: low
  Catalyst Pharmaceuticals, Inc. filed an 8-K on February 28, 2024, reporting on 'Other Events' and 'Financial Statements and Exhibits'. The filing indicates no s
• Catalyst Pharma's Santhera Investment: $5.9M Paid by Year-End — 10-K · 2024-02-28T00:00:00.000Z [neutral] Risk: medium
  CATALYST PHARMACEUTICALS, INC. filed its 10-K on February 28, 2024, for the fiscal year ending December 31, 2023. The company reported an investment in Santhera
• Catalyst Pharma Files 8-K on Other Events and Exhibits — 8-K · 2024-02-21T00:00:00.000Z [neutral] Risk: low
  CATALYST PHARMACEUTICALS, INC. filed an 8-K on February 21, 2024, reporting 'Other Events' and 'Financial Statements and Exhibits'. The filing indicates a curre
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• Deerfield Mgmt Exits Catalyst Pharma (CPRX) Position — SC 13G/A · 2024-02-12T00:00:00.000Z [bearish] Risk: medium
  Deerfield Mgmt, L.P. and its affiliates, including Deerfield Management Company, L.P. and Deerfield Partners, L.P., have filed an amended SC 13G/A for Catalyst
• State Street Amends Passive Stake in Catalyst Pharma — SC 13G/A · 2024-01-25T00:00:00.000Z [neutral]
  State Street Corp, a major financial institution, filed an amended SC 13G/A on January 25, 2024, indicating its ownership of Catalyst Pharmaceuticals Inc. commo
• BlackRock Amends Catalyst Pharma Stake (SC 13G/A) — SC 13G/A · 2024-01-22T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 22, 2024, indicating a change in their ownership of Catalyst Pharmaceuticals Inc. common stock as of Decembe
• Catalyst Pharma Files 8-K, Confirms NASDAQ Listing — 8-K · 2024-01-09T00:00:00.000Z [neutral]
  Catalyst Pharmaceuticals, Inc. filed an 8-K on January 9, 2024, to report an "Other Event" and "Financial Statements and Exhibits." This filing primarily serves
• Catalyst Pharma Confirms NASDAQ Listing in 8-K Filing — 8-K · 2024-01-08T00:00:00.000Z [neutral]
  Catalyst Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to disclose that its common stock, with a par value of $0.001 per share, is registered on the NA
• Catalyst Pharma Files 8-K on Material Agreement; Details Pending — 8-K · 2024-01-05T00:00:00.000Z [neutral]
  On January 4, 2024, Catalyst Pharmaceuticals, Inc. filed an 8-K to report an "Entry into a Material Definitive Agreement" and "Regulation FD Disclosure." While